The cannabis stocks we’ve weeded out don’t generate a lot of attention, but probably should based on their 2019 performance thus far
SmallCapPower | July 15, 2019: When you think of cannabis companies, the first names that come to mind are likely the most publicized ones, such as Canopy Growth Corporation, Aurora Cannabis Inc, and Aphria. Since there are more than 100 marijuana stocks in the market, there are some that fly under the radar. Today we have discovered four lesser-known cannabis stocks that have made big moves so far in 2019.
*Share prices as at close Thursday, July 11, 2019, data obtained from S&P Capital IQ
Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) – $14.40
Zynerba is a U.S.-based specialty pharmaceutical company with a focus on the development of innovative pharmaceutical products, including cannabinoids, delivered via dermal solutions to treat neurological disorders. On June 11, Zynerba Pharmaceuticals announced that the U.S. Patent and Trademark Office has issued a patent to Zynerba Pharmaceuticals titled “Treatment of Autism Spectrum Disorder with Cannabidoil,” which includes claims directed to methods treating autism spectrum disorder by administering an effective amount of synthetic cannabidiol.
- Market Cap: $303.3M
- YTD Return: 384.3%
- 90 Day Return: 66.9%
- 90 Day Average Trading Volume: 2,340,000
Benchmark Botanics Inc. (CSE:BBT) – $0.59
Operating out of British Columbia, Benchmark Botanics is a cultivator and producer of pharmaceutical-grade medical and recreational cannabis. The Company carries out its cultivating and harvesting activities from its facility in Peachland, BC, a 12,700 square foot indoor Peachland Cannabis Complex. Benchmark’s Peachland Cannabis Complex is expected to have 62,700 square feet of operating space for future production of high-quality cannabis and cannabis products. On June 6, the Company announced that it has closed its private placement for $11.3M at $0.40/unit.
Australis Capital Inc. (CSE:AUSA) – $1.02
Australis Capital is a cannabis-focused company spun out from Aurora Cannabis Inc to take advantage of the rapidly-growing U.S. cannabis market. Australis was spun off from Aurora in late 2018, since Aurora is prohibited from investing in U.S. cannabis assets due to TSX and NYSE listing rules. AUSA has acquired a range of assets across the industry, with a focus on durable assets and those that can be leveraged across multiple geographies, such as brands, IP, and technology.
Sproutly Canada Inc. (CSE:SPR) – $0.63
Sproutly is focused on supplying cannabis to the beverage and edibles market. The Company has a Toronto-based ACMPR licensed facility that was built to cultivate pharmaceutical-grade cannabis to help create the first natural, truly water-soluble cannabis solution. Through a Joint Venture with Moosehead Breweries, the Company has created INFUZ2O technology, which allows the user to feel the effects of cannabis in less than five minutes and is expected to take less than 90 mins to wear off. On June 20, 2019, the Company announced it had successfully completed the first run of its proprietary Aqueous Phytorecovery Process extraction technology that it licensed from Infusion Biosciences Inc. This recovery process is used in the production of INFUZ2O. On June 17, 2019, the Company announced its first commercial sale of cannabis flower in Canada.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below: